Claims

1. A compound of formula (I)



(I)

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:

R_1 is H, R_2 is F and R_3 is H, F or CH_3;

R_1 is F or CH_3, R_2 is OCH_3 and R_3 is H;

R_1 is F, R_2 is H and R_3 is CH_3;

R_1 is H, R_2 is OCH_3 and R_3 is H;

R_1 is H, R_2 is Cl and R_3 is H or CH_3;

R_1 is F, R_2 is F and R_3 is H or

R_1 is CH_3, R_2 is H and R_3 is F.

2. A pharmaceutical composition comprising a compound of formula (I) or a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A compound of formula (I) or a stereo- isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use as a medicament.

4. A compound of formula (I) or a stereo- isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 3 for use in the treatment of dengue.

5. A use of a compound represented by the following structural formula (I)



a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:
R_1 is H, R_2 is F and R_3 is H, F or CH_3;
R_1 is F or CH_3, R_2 is OCH_3 and R_3 is H;
R_1 is F, R_2 is H and R_3 is CH_3;
R_1 is H, R_2 is OCH_3 and R_3 is H;
R_1 is H, R_2 is Cl and R_3 is H or CH_3;
R_1 is F, R_2 is F and R_3 is H or
R_1 is CH_3, R_2 is H and R_3 is F.

in the manufacture of a medicament for inhibiting the replication of dengue virus(es) in a patient.

6. The use of a compound according to claim 5 further comprising an additional therapeutic agent.

7. The use of claim 6 wherein said additional therapeutic agent is selected from an antiviral agent or dengue vaccine, or both.

8. A use of a compound represented by the following structural formula (I)



a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:

R_1 is H, R_2 is F and R_3 is H, F or CH_3;

R_1 is F or CH_3, R_2 is OCH_3 and R_3 is H;

R_1 is F, R_2 is H and R_3 is CH_3;

R_1 is H, R_2 is OCH_3 and R_3 is H;

R_1 is H, R_2 is Cl and R_3 is H or CH_3;

R_1 is F, R_2 is F and R_3 is H or

R_1 is CH_3, R_2 is H and R_3 is F.

for inhibiting the replication of dengue virus(es) in a biological sample.